TMB is a genomic biomarker that prediction of response to immune checkpoint inhibitors (ICIs) such as PD-(L)1 inhibitors. The number of somatic mutations within the coding region of a tumor genome is regarded as TMB, which is associated with response to ICIs. Leveraging our whole exome sequencing (WES) sequencing technologies and a proprietary algorithmic approach for TMB analysis, we support TMB analysis services for assessing the response to checkpoint inhibitor immunotherapy.